RESUMO
BACKGROUND: Antibody-mediated rejection is one of the most significant risk factors for allograft dysfunction and failure in children and adolescents with kidney transplants, yet optimal treatment remains unidentified. To date, there are mixed findings regarding the use of Bortezomib, a plasma cell apoptosis inducer, as an adjunct therapy in the treatment of antibody-mediated rejection. METHODS: In a retrospective single center study, we reviewed the efficacy and tolerability of bortezomib as adjunct therapy for treatment-refractory antibody-mediated rejection. RESULTS: Six patients with a median age of 14.6 years (range 6.9-20.1 years) received bortezomib at a mean of 71 months (range 15-83 months) post-kidney transplant. Four patients experienced decline in estimated glomerular filtration rate (eGFR) from 4% to 42%. One patient started bortezomib while on hemodialysis and did not recover graft function, and another patient progressed to hemodialysis 6 months after receiving bortezomib. Although DSA did not completely resolve, there was a statistically significant decline in DSA MFI pre and 12-months post-BZ (p = .012, paired t-test) for the subjects who were not on dialysis at the time of bortezomib. Chronic Allograft Damage Index (CADI) score of ≥3 was seen in all six subjects at their biopsy prior to therapy. No adverse effects were reported. CONCLUSIONS: Bortezomib was well tolerated and resulted in improvements in MFI of DSA among four pediatric subjects without allograft failure, although no effects were observed on eGFR trajectory. Further studies are needed to clarify whether earlier intervention with bortezomib could prevent renal failure progression.
Assuntos
Bortezomib , Taxa de Filtração Glomerular , Rejeição de Enxerto , Transplante de Rim , Humanos , Bortezomib/uso terapêutico , Rejeição de Enxerto/prevenção & controle , Rejeição de Enxerto/imunologia , Estudos Retrospectivos , Masculino , Adolescente , Feminino , Criança , Adulto Jovem , Resultado do Tratamento , Imunossupressores/uso terapêutico , Isoanticorpos/imunologiaRESUMO
BACKGROUND: We report follow-up data from an ongoing prospective cohort study of COVID-19 in pediatric kidney transplantation through the Improving Renal Outcomes Collaborative (IROC). METHODS: Patient-level data from the IROC registry were combined with testing, indication, and outcomes data collected to describe the epidemiology of COVID testing, treatment, and clinical outcomes; determine the incidence of a positive COVID-19 test; describe rates of COVID-19 testing; and assess for clinical predictors of a positive COVID-19 test. RESULTS: From September 2020 to February 2021, 21 centers that care for 2690 patients submitted data from 648 COVID-19 tests on 465 patients. Most patients required supportive care only and were treated as outpatients, 16% experienced inpatient care, and 5% experienced intensive care. Allograft complications were rare, with acute kidney injury most common (7%). There was 1 case of respiratory failure and 1 death attributed to COVID-19. Twelve centers that care for 1730 patients submitted complete testing data on 351 patients. The incidence of COVID-19 among patients at these centers was 4%, whereas the incidence among tested patients was 19%. Risk factors to predict a positive COVID-19 test included age > 12 years, symptoms consistent with COVID-19, and close contact with a confirmed case of COVID-19. CONCLUSIONS: Despite the increase in testing and positive tests over this study period, the incidence of allograft loss or death related to COVID-19 remained extremely low, with allograft loss or death each occurring in < 1% of COVID-19-positive patients and in less than < 0.1% of all transplant patients within the IROC cohort. A higher resolution version of the Graphical abstract is available as Supplementary information.
Assuntos
COVID-19 , Transplante de Rim , Humanos , Criança , Transplante de Rim/efeitos adversos , Teste para COVID-19 , Seguimentos , Estudos ProspectivosRESUMO
Heritable connective tissue disorders are a group of diseases, each rare, characterized by various combinations of skin, joint, musculoskeletal, organ, and vascular involvement. Although kidney abnormalities have been reported in some connective tissue disorders, they are rarely a presenting feature. Here we present three patients with prominent kidney phenotypes who were found by whole exome sequencing to have variants in established connective tissue genes associated with Loeys-Dietz syndrome and congenital contractural arachnodactyly. These cases highlight the importance of considering connective tissue disease in children presenting with structural kidney disease and also serves to expand the phenotype of Loeys-Dietz syndrome and possibly congenital contractural arachnodactyly to include cystic kidney disease and cystic kidney dysplasia, respectively.
Assuntos
Aracnodactilia/genética , Contratura/genética , Fibrilina-2/genética , Síndrome de Loeys-Dietz/genética , Receptor do Fator de Crescimento Transformador beta Tipo I/genética , Proteína Smad2/genética , Adolescente , Aracnodactilia/complicações , Aracnodactilia/diagnóstico por imagem , Aracnodactilia/patologia , Criança , Tecido Conjuntivo/patologia , Doenças do Tecido Conjuntivo/complicações , Doenças do Tecido Conjuntivo/diagnóstico por imagem , Doenças do Tecido Conjuntivo/genética , Doenças do Tecido Conjuntivo/patologia , Contratura/complicações , Contratura/diagnóstico por imagem , Contratura/patologia , Predisposição Genética para Doença , Humanos , Rim/diagnóstico por imagem , Rim/patologia , Doenças Renais Císticas/complicações , Doenças Renais Císticas/genética , Doenças Renais Císticas/patologia , Síndrome de Loeys-Dietz/complicações , Síndrome de Loeys-Dietz/diagnóstico por imagem , Síndrome de Loeys-Dietz/patologia , Masculino , Mutação/genética , Fenótipo , Anormalidades da Pele/complicações , Anormalidades da Pele/genética , Anormalidades da Pele/patologia , Sequenciamento do ExomaRESUMO
INTRODUCTION: The Children's Hospital of Philadelphia (CHOP) Global Health Allies program in the Dominican Republic trains nine health promoters (HPs) in various health subjects with the goal to educate the community. This time we evaluated our teaching session on sleep and sleep disorders. METHODS: Questionnaires were randomly administered to HPs, and community members in the Dominican Republic before and after the HP educational intervention. Nine HPs already enrolled in the CHOP program, received a 4-hour training session in sleep and sleep disorders. HPs were then instructed to educate the community as they usually do during their supervised weekly home visits. RESULTS: The nine HP demonstrated knowledge of sleep disorders in their post-training assessment. In the community, 93 adults responded to the initial questionnaire. Although 92 (99%) stated that sleep is important, very few knew about obstructive sleep apnea (n = 17; 18%) and narcolepsy (n = 11; 12%). The post-education questionnaire revealed no statistically significant change in the knowledge about sleep and sleep disorders in the community. CONCLUSION: The HP knowledge about sleep disorders improved after a 4-hour training session. The community knowledge did not change after education by HPs. Barriers to community education must be explored and the need for other forms of community education about sleep and sleep disorders should be addressed.